EE162 Cost-Effectiveness of Obinutuzumab Plus Bendamustine and Followed by Obinutuzumab Maintenance Therapy in Chinese Patients With Relapse and Refractory Follicular Lymphoma
Abstract
Authors
J Ma B Zhen Y Xia Q Gong Y Li W Chen